Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

Background and aim: Obesity is a risk factor for progression of fibrosis in chronic liver diseases such as non-alcoholic fatty liver disease and hepatitis C. The aim of this study was to investigate the longer term effect of weight loss on liver biochemistry, serum insulin levels, and quality of life in overweight patients with liver disease and the effect of subsequent weight maintenance or regain. Patients: Thirty one patients completed a 15 month diet and exercise intervention. Results: On completion of the intervention, 21 patients (68%) had achieved and maintained weight loss with a mean reduction of 9.4 (4.0)% body weight. Improvements in serum alanine aminotransferase (ALT) levels were correlated with the amount of weight loss (r = 0.35, p = 0.04). In patients who maintained weight loss, mean ALT levels at 15 months remained significantly lower than values at enrolment (p = 0.004), while in regainers (n = 10), mean ALT levels at 15 months were no different to values at enrolment (p = 0.79). Improvements in fasting serum insulin levels were also correlated with weight loss (r = 0.46, p = 0.04), and subsequent weight maintenance sustained this improvement. Quality of life was significantly improved after weight loss. Weight maintainers sustained recommended levels of physical activity and had higher fasting insulin levels (p = 0.03) at enrolment than weight regainers. Conclusion: In summary, these findings demonstrate that maintenance of weight loss and exercise in overweight patients with liver disease results in a sustained improvement in liver enzymes, serum insulin levels, and quality of life. Treatment of overweight patients should form an important component of the management of those with chronic liver disease.

[1]  Hideo Ayame,et al.  [The Da Qing IGT and Diabetes study]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[2]  D. Purdie,et al.  In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. , 2003, Journal of hepatology.

[3]  A. Clouston,et al.  Interaction of non-alcoholic fatty liver disease with other liver diseases. , 2002, Best practice & research. Clinical gastroenterology.

[4]  K. Eguchi,et al.  Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults , 2002, American Journal of Gastroenterology.

[5]  D. Purdie,et al.  Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C , 2002, Gut.

[6]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[7]  A. McCullough,et al.  Update on nonalcoholic fatty liver disease. , 2002, Journal of clinical gastroenterology.

[8]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[9]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[10]  R. Fontana,et al.  Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C , 2001, American Journal of Gastroenterology.

[11]  K. Fontaine,et al.  Obesity and health‐related quality of life , 2001, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[12]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[13]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[14]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[15]  G. Blackburn,et al.  Obesity prevalence by age group and 5-year changes in adults residing in rural Wisconsin. , 2000, Journal of the American Dietetic Association.

[16]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[17]  J. Ware,et al.  Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response , 1999, Hepatology.

[18]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[19]  K. Fujioka,et al.  Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. , 1999, The American journal of clinical nutrition.

[20]  A. Clouston,et al.  Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis , 1999, Hepatology.

[21]  H. Bonkovsky,et al.  Reduction of health‐related quality of life in chronic hepatitis C and improvement with interferon therapy , 1999, Hepatology.

[22]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[23]  H. Thomas,et al.  Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis , 1998, Hepatology.

[24]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[25]  E. Ravussin,et al.  Reduced insulin secretion: an independent predictor of body weight gain. , 1995, The Journal of clinical endocrinology and metabolism.

[26]  R. Hamman,et al.  High fasting insulin levels associated with lower rates of weight gain in persons with normal glucose tolerance: the San Luis Valley Diabetes Study. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[27]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[28]  John E. Ware,et al.  The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection , 1992, Medical care.

[29]  Arthur M. Nezu,et al.  Effect of length of treatment on weight loss. , 1989, Journal of consulting and clinical psychology.

[30]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[31]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[32]  Diagnosis and classification of diabetes mellitus. , 2004, Diabetes care.

[33]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.